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PREDICTIVE FACTORS FOR RESPONSE TO LAMIVUDINE IN CHRONIC HEPATITIS B
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SUMMARY
Background: Lamivudine has been shown to be an efficient drug for chronic hepatitis B (CHB) treatment.
Aim: To investigate predictive factors of response, using a quantitative method with high sensitivity.
Methods: We carried out a prospective trial of lamivudine in 35 patients with CHB and evidence for viral replication, regardless
to their HBeAg status. Lamivudine was given for 12 months at 300 mg daily and 150 mg thereafter. Response was considered when
DNA was undetectable by PCR after 6 months of treatment. Viral replication was monitored by end-point dilution PCR. Mutation
associated with resistance to lamivudine was detected by DNA sequencing in non-responder patients.
Results: Response was observed in 23/35 patients (65.7%) but only in 5/15 (33.3%) HBeAg positive patients. Only three pre-
treatment variables were associated to low response: HBeAg (p = 0.006), high viral load (DNA-VHB > 3 x 106 copies/ml) (p = 0.004)
and liver HBcAg (p = 0.0028). YMDD mutations were detected in 7/11 non-responder patients.
Conclusions: HBeAg positive patients with high viral load show a high risk for developing drug resistance. On the other hand,
HBeAg negative patients show a good response to lamivudine even with high viremia.
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INTRODUCTION
Chronic hepatitis caused by hepatitis B virus (HBV) may lead to
cirrhosis, liver failure and hepatocellular carcinoma. The current treatment
with interferon-α (IFN-α) remains unsatisfactory, as it is effective in
fewer than 40 percent of patients34, and previous treatment with
corticosteroid is still in use to improve results18.
Lamivudine (2’, 3’-dideoxy-3’-tiacytidine) is a potent inhibitor of
viral DNA polymerase and is considered one of the most promising
nucleoside analog. Following entering the cells, lamivudine is
phosphorylated to its active metabolite, lamivudine-5’-triphosphate,
by the 2’-deoxycytidine kinase and other cellular kinase enzymes35. It,
then, interferes with the reverse-transcriptase activity of the HBV
polymerase, terminating the nascent viral DNA chain and inhibiting
DNA synthesis37.
According to a preliminary study carried out by DIENSTAG et al.,
daily doses of 100 and 300 mg of lamivudine reduced HBV-DNA to
undetectable levels in all patients during a six month therapy; but
sustained undetectable levels of HBV-DNA and hepatitis-B e antigen
(HBeAg) occurred in only 5-12% of the treated patients6. In an extended
study for up to 18 months, with 23 patients who had remained HBeAg
positive after six months of therapy, the same research group observed
that HBV-DNA suppression was maintained during therapy in 20 (87%)
of these patients. Whereas, HBeAg became negative in 39% of the
patients7 .
A recent report showed that HBV-DNA levels in serum may decrease
below the detection threshold of the Polymerase Chain Reaction (PCR)
assay in 46% of 51 patients, after a 24-week course of lamivudine12 . A
trend towards a deeper suppression of viral replication with a daily dose
of 300 mg was also observed12. Such efficacy of lamivudine to impair
HBV replication was also shown in HIV-infected8 and in transplanted
patients23, 28, 29.
Daily doses of lamivudine in patients with chronic hepatitis B (CHB)
has varied widely, ranging from 5 to 600 mg. Doses above 5 mg
reproducibly decreased HBV-DNA levels in serum8, but doses of 100
mg and 300 mg can reduce viremia to an undetectable level6. Daily doses
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of 300 mg may lead to an earlier6 and more profound suppression of
HBV DNA12.
Viral resistance to lamivudine is associated with mutations which
lead to amino acid substitutions in the highly conserved Tyr-Met-Asp-
Asp (YMDD) motif, in the active site of the polymerase22 . The appearance
of such mutation (Methyonine to Isoleucine or Valine) may explain the
viral “breakthrough” during lamivudine therapy5, 7, 25, 28.
Despite the reported efficacy of lamivudine in patients not previously
treated and in those who had not responded to interferon therapy6,
additional data are needed to evaluate whether there is a difference in
response to lamivudine in these two groups of patients.
The level of viral nucleic acid in serum appears to be an early indicator
for the effectiveness of therapy31. Few studies have evaluated the efficacy
of lamivudine with more sensitive quantitative methods, including the
end-point dilution method27, specially in patients undergoing long-term
treatment12.
The aim of this study was to assess the efficacy and safety of
lamivudine in two groups of Brazilian patients with different degrees of
CHB; one who had not been previously treated with any drug (12
patients), and another after failure of IFN-α treatment (23 patients).
The present study revealed an as yet not described correlation between
viral load and response to lamivudine.
PATIENTS AND METHODS
Patients
We carried out an open and prospective trial of lamivudine in 35
consecutive patients with CHB with evidence of viral replication. Eligible
patients included 30 men and 5 women, ranging from 9 to 72 years old.
All had hepatitis B surface antigen (HBsAg) in serum for at least six
months, detectable HBV-DNA in serum (34 by PCR and one by bDNA)
and alanine aminotransferase (ALT) levels ranging from normal levels
to 10 times the upper normal limit (UNL).
The inclusion criteria were broad, allowing the enrollment of patients
with low transaminase levels as well as patients with low degree of
hepatitis, on one side, and patients with compensated (Child-Pugh A)
and decompensated (Child-Pugh B) cirrhosis on the other side30.
Patients were excluded if they were also infected with hepatitis C
virus, hepatitis D virus or human immunodeficiency virus (HIV), had
other serious medical illness, another type of liver disease or an advanced
decompensated liver disease (Child-Pugh C), or were pregnant or
lactating.
Patients consecutively attended from March 1996 to July 1997 were
considered for treatment with lamivudine on a daily dose of 300 mg for
12 months and 150 mg thereafter. Only 4 patients with decompensated
liver cirrhosis (Child-Pugh B) received 150 mg from the beginning.
Thirty five patients have been enrolled, being 30 under lamivudine
treatment and most of them for longer than 6 months (long term
treatment). Lamivudine was withdrawn from five patients who presented
YMDD mutation after nine months of treatment (4 with YVDD and one
with YIDD mutations).
Patients were divided in two groups: Group I included 12 patients
who had not been previously treated (“naive”) and, Group II, 23 patients
who had been previously treated with interferon-α (IFN-α). Resistance
to IFN-α was considered as partial in case of HBeAg clearance and
persistence of HBV-DNA detected by PCR (15 patients). Complete
resistance was defined as persistence of HBeAg and HBV-DNA (8
patients). None of these patients received immunosuppressive or antiviral
therapy at least 6 months before lamivudine therapy.
Biopsies
Liver biopsy was performed using a Tru-Cut needle in 25 patients,
but not in the remaining 10, due to coagulation disturbances or ascitis.
In the latter cases, a clinical and ultrasonographic diagnosis of cirrhosis
was performed. Liver histology was blindly evaluated by two specialized
pathologists.
Immunohistochemistry
HBsAg and Hepatitis B core antigen (HBcAg) detection in liver
tissue was carried out using monospecific polyclonal antibodies in the
high-sensitive streptavidin-biotin-peroxidase system (LSAB, Dako,
USA), after blockage of endogenous biotin and peroxidase32.
Serology
Detection of HBsAg, HBeAg and antibodies to hepatitis B e antigen
(anti-HBe) in serum samples were carried out by ELISA, using
commercially available kits (Abbott Laboratories, North Chicago, IL,
USA).
Detection of HBV-DNA by Polymerase Chain Reaction (PCR)
HBV-DNA was detected by a nested PCR as previously described15,
16
.
 Serum samples (10 µl) were denatured with 2.5 µl of NaOH 0.5 M
and incubated at 37 oC for one hour. Samples were neutralized with 2.5
µl of HCl 0.5 M. For the first round, 1 µM of each primer [1763 (5’TTG
GGG CAT GGA CAT TGA CCC GTA TAA 3’) and 2032R (5’CTG
ACT AAT TCC CTG GAT GGG TCT 3’)] were added to the mixture.
Amplification was achieved in a thermocycler model 480 (Perkin Elmer,
USA), in 25 cycles of 94 oC for 1 minute (min.), 42 oC for 1 min. and 72
oC for 2 min., followed by an extension step at 72 oC for 5 min. In the
second round, 1:10 of the first round product was amplified by primers
1778 (5’CAT TGA CCC GTA TAA AGA ATT 3’) and 2017 (5’CTG
GAT GCT GGG TCT TCC AAA 3’), in the same conditions as above.
Amplified products from the second round were electrophoresed in a
2% agarose gel, stained with Ethidium Bromide and visualized under
ultra-violet light.
To avoid false-positive results, strict procedures proposed for nucleic
acid amplification techniques were followed19.
Detection of mutations associated with resistance to Lamivudine
HBV-DNA positive samples were also amplified with primers
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corresponding to the HBV polymerase gene, targeted to the region of
mutations associated with lamivudine resistance. Serum samples were
denatured and neutralized as described above and submitted to nested
PCR. The outer primers 5’LAM 5 (5’TGC RYY TGT ATT CCC ATC
CCA TC 3’) and 3’LAM 2 (5’GTT TTG TTA GGG TTT AAA TG 3’)
were used in the first round, while the inner primers L840 (5’ACC CCA
TCT TTT TGT TTT GTT AAG 3’) and L372 (5’TCG CTG GAT GTG
TCT GCG GCG TTT TAT 3’) were used in the second round.
Amplification for the first and second round was carried out at 94 oC for
1 min., followed by 35 cycles of 94 oC for 30s, 42 oC for 30s and 72 oC
for 40s and a final extension step at 72 oC for 7 min in a PTC-100
thermocycler (M J Research, Watertown, MA, USA)1, 2 .
Sequencing
PCR products were submitted to cycle sequencing reactions, using
the second round primers described above and the ABI PRISMR BigDyeTM
Terminator Cycle Sequencing Ready Reaction Kit with AmpliTaqR DNA
Polymerase, FS (PE Biosystems, Foster City, CA, USA). Nucleotide
sequences from both strands were determined in an Automated DNA
sequencer model ABI 310 FS (PE Biosystems, Foster City, CA, USA).
Sequences were compared with those previously described in the
literature using the Lasergene program (DNAstar, Madison, WI, USA).
Quantification of HBV DNA
HBV viremia was followed in sequential samples from the patients
using an in-house end-point dilution PCR, or simply EPD method.
Samples were initially diluted in water to a 10-fold series till 1010.
Each dilution was submitted to the same PCR protocol described above
for detection of HBV-DNA. As the sensitivity of the method was reported
to be around 3 copies per 10 µl or 300 copies/ml15, 16, quantitative results
were estimated by multiplying the least positive dilution by 3 x 102 copies/
ml.
Assessment of response
Patients were considered as responders if HBV-DNA was
undetectable by PCR at the sixth month of treatment.
Other endpoints such as HBeAg clearance, HBeAg to anti-HBe
seroconversion and disappearance of HBsAg were also investigated.
HBeAg clearance was defined as the absence of HBeAg in two
consecutive samples.
Statistical analysis
Univariate analysis for non-responder and responder patients were
performed according to the Chi-square (χ2) and Fisher’s Exact Test, taking
into consideration the following variables: sex, previous treatment with
IFN-α, viremia, presence of serum HBeAg, HBcAg in situ, and liver
cirrhosis. Age and pre-treatment ALT levels were analysed using the
Student’s t-test. Pre-treatment ALT levels were also analysed by the non-
parametric Mann-Whitney-Wilcoxon test. This test was also used to
analyse the viral load median (represented by the log of the number of
genomes/ml) in the two groups. For viral load analysis, we also compared
two groups with high viremia (> 3x106) and low viremia (< 3x106) by
the Chi-square test.
The logistic regression technique was performed to estimate the
probability of non-response based on variables that demonstrated
statistical significance in the univariate analyses. The stepwise method
was used to select the variables more associated with the probability of
non-response.
The level of significance was 5% (α = 0.05); and the SAS software
(Statistical Analysis System, SAS Institute, NC, USA) was used.
All patients gave informed consent for the study, which was approved
by the Local Ethics Committee.
RESULTS
Therapy efficacy
Lamivudine therapy induced a rapid decrease in serum HBV-DNA
concentration in 27 out of 29 patients (93.1%) whose quantification was
performed after 12 weeks of treatment: 14 (51.9%) had undetectable
HBV-DNA, and 13 (48.1%) showed a decrease in viremia. The other 2
patients presented no change in the HBV-DNA concentration (Table 1
and Table 2). At the sixth month of treatment, chosen as the time point
to define response in this study, HBV-DNA was undetectable in the serum
Table 1
HBV-DNA levels (log of genomes/ml) in the Responder Group
Patient Sex Age Group PCR (log genomes/ml)
Pre 12 weeks 24 weeks
1 M 17 I 3 NEG NEG
3 M 29 I 4 NEG NEG
5 M 72 I 10 3 NEG
6 M 62 I 12 4 NEG
8 F 9 I 8 NEG NEG
9 M 59 I 9 2 NEG
10 M 47 I 4 NEG NEG
12 M 67 I 6 3 NEG
14 M 33 II 3 NEG NEG
15 M 27 II 4 NEG NEG
19 M 48 II 3 ND NEG
20 M 46 II 8 NEG NEG
24 M 29 II 3 NEG NEG
25 M 72 II 3 NEG NEG
26 M 37 II 10 6 NEG
27 F 18 II 3 NEG NEG
28 F 37 II 6 6 NEG
30 M 49 II 6 ND NEG
31 M 43 II 3 NEG NEG
32 M 32 II 3 NEG NEG
33 M 24 II 8 3 NEG
34 M 50 II 4 ND NEG
35 M 45 II 6 (a) 4 NEG
Sex (M = male, F = female); Age (years); Group (I  = no previous treatment;
II = previous treatment with Interferon-α); (a) = bDNA; ND = not done; NEG
= negative.
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66.355). For this reason, the variable log of number of genomes (G), as
determined by EPD-PCR, was selected and the model was written as
follows, where p is the probability of non-response to lamivudine.
In this model, the variable G assumes continuous values from 3 to
12. The estimated odds-ratio (1.473; 95% confidence interval, 1.109 to
1.958) showed that the chance of non-response increases 1.5 times for
each increase of one log in the viral load, as shown in Figure 1.
The HBV-DNA levels (log of genomes/ml) found for responders
are shown in Table 1 and for non-responders in Table 2.
All but one non-responder patients at the sixth month persisted as
PCR-positive at the twelfth month, regardless of their viremia level by
PCR. On the other hand, all but one responder patients were PCR negative
at the twelfth month.
Serum HBV markers
At the sixth month of therapy, HBeAg became negative in only 3
(20%) out of 15 patients. Among the remaining 12 HBeAg positive, 5
(42%) became negative after one year of therapy. HBeAg negativation
was followed by anti-HBe seroconversion in all responder patients; in
one patient, HBeAg disappeared only after 21 months of therapy.
Interestingly, despite the detection of HBV-DNA and YVDD mutation,
the HBeAg antigen became negative in one non-responder. Moreover,
HBsAg clearance was observed in only one responder patient, after 20
months of therapy.
Table 2
HBV-DNA levels (log of genomes/ml) in the Non-Responder Group
Patient Sex Age Group PCR (log genomes/ml)
Pre 12 weeks 24 weeks
2 F 22 I 10 3 4
4 M 42 I 10 4 3
7 M 51 I 12 NEG 4
11 M 11 I 10 6 4
13 M 27 II 10 10 6
16 M 30 II 8 NEG 4
17 M 65 II 12 4 7
18 M 48 II 10 4 3
21 M 44 II 10 ND 3
22 F 23 II 3 ND 4
23 M 25 II 3 ND 3
29 M 60 II 10 6 4
Sex (M = male, F = female); Age (years); Group (I  = no previous treatment;
II = previous treatment with Interferon-α); ND = not done; NEG = negative.
of 23 out of 35 patients (65.7%) (responder group). The relevant
characteristics of the 23 responder and the 12 non-responder patients
are shown in Table 3.
There were no significant differences between the two groups
(responders and non-responders) with respect to age, gender, response
to previous interferon treatment, base-line alanine aminotransferase levels
and degree of liver injury, as shown by the semi-quantification of the
stage or grade of inflammation in each liver compartment.
Only three pre-treatment variables were statistically associated with
low response to lamivudine: HBeAg positivity (p = 0.006), high viral
load (p = 0.004) and HBcAg in situ immune-expression (p = 0.028)
(Table 3). Fourteen (93%) out of the 15 HBeAg positive serum presented
high viremia at baseline (greater than 3 x 106 genomes/ml); and response
to lamivudine at the sixth month was observed in 5 (36%) of these 14
patients . Baseline low viremia was observed in one HBeAg-positive
patient who responded to lamivudine. Of the 20 HBeAg-negative at the
baseline, 3 (15%) patients presented high and 17 (85%) low viremia, of
whom, 2 and 15, respectively, responded to lamivudine after the sixth
month. As a whole, a lack of parallelism was seen between HBeAg
positivity and degree of viremia in 4 (11%) out of 35 patients. The
presence of HBcAg was significantly related to the presence of HBeAg
in sera (Fisher’s Exact Test: p = 0.002).
Levels of viral load at pre-treatment was correlated with response to
lamivudine in two ways: when comparing patients with high ( > 3x106
genomes/ml) and low viremia (≤ 3x106 genomes/ml) (p = 0.004), and
when analyzing the log of number of such values using a non–parametric
test (p = 0.006).
The stepwise method selected two variables associated with response
to lamivudine: high or low viremia (genomes/ml) and level of viremia
(log genomes/ml). With the first variable, the probability of non-response
to lamivudine is 11.4 times higher in patients with high viremia (> 3x106
genomes/ml), with a very wide 95% confidence interval (1.938 to Fig. 1 - Probability of non-response according to the regression model.
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Table 3
Characteristics of the 35 patients at baseline and comparison between responder and non-responder. Patients were considered “responders” if presented
undetectable HBV-DNA by PCR at the sixth month of treatment
Variable Responder (%) Non-responder (%) Total p Test
(23 patients) (12 patients)
Male/female 20 : 3 10 : 2 35 1.00 Fisher
Age (mean; SD) 41.4 ; 17.5 37.3 ; 16.8 35 0.51 Student’s
HBeAg positive   6 (40) 9 (60) 15
0.006 χ2
HBeAg negative 17 (85) 3 (15) 20
Non-cirrhosis 15 (65) 8 (35) 23
1.00 Fisher
Cirrhosis 8 (67) 4 (33) 12
Previous IFN-α:   Yes 15 (65) 8 (35) 23
1.00 Fisher
                             No 8 (76) 4 (33) 12
Pre-treatment
ALT (x UNL)
(mean; SD) 2.66 ;  2.95 1.33 ;  0.86 35 0.054 Student’s
Pre-treatment
ALT (x UNL(*))
(median) 1.26 0.97 35 0.37 Mann-Whitney-Wilcoxon
Viral load (median of 4 10 34 (*) 0.006 Mann-Whitney-Wilcoxon
log genomes/ml)
Viremia(genomes/ml):
High  (>3x106) 7 (41) 10 (59) 17 0.004 χ2
Low  (≤3x106) 15 (88) 2 (12) 17
HBcAg  in situ:
Positive 4 (40) 6 (60) 10 0.028 Fisher
Negative 13 (87) 2 (13) 15
 (*)
 One patient was excluded because his pre-treatment viral load was determined only by bDNA. SD = Standard Deviation; UNL = upper normal limit.
Serum alanine aminotransferase (ALT) activity:
Serum ALT activity was determined in 33 patients at the sixth month.
Of 18 patients with increased ALT level at baseline, 12 became normal
(including three non-responders). Whereas of 15 patients with normal
ALT at baseline, only one non-responder showed an increased ALT level
after 6 months of treatment. Therefore, lamivudine was equally effective
at suppressing viral load among patients with normal and elevated ALT
levels (Table 3).
The seven patients with lamivudine resistance and YMDD mutations
(see below) showed a slight elevation of the ALT level (0.5 to 3.0 times
the upper normal limit) with abnormal values in four of them. No
biochemical flare was observed, except in one patient during an one-
month association of famciclovir.
Previous treatment with Interferon-α
As shown in Table 3, no difference was found between Group I
(naive of treatment) and Group II [resistant to Interferon-α (IFN-α)].
However, considering the pattern of previous response to IFN-α , we
observed a trend (Fisher’s Exact Test: p = 0.058) to a better response to
lamivudine in patients who had shown a partial response (12 out of 15
patients) as compared to those who did not respond (3 out of 8 patients)
to IFN-α, respectively.
As for HBV-DNA levels, a baseline high viremia was detected in 8
out of 12 patients naive of treatment and in 9 out of 23 interferon-resistant
patients, with a response to lamivudine of 50% and 33%, respectively.
On the other hand, a baseline low viremia was observed in 4 out of 12
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naive patients and in 14 out of 23 Interferon - resistant patients, with a
response frequency of 100% and 86%, respectively. No statistical
significant difference was found in both cases.
Resistance to Lamivudine
Of the 12 non-responders to lamivudine, samples of 11 were
sequenced for the YMDD motif of the C region, and 7 (64%) of them
showed mutations associated with lamivudine resistance. Six (55%)
patients showed a YVDD mutation and one (9%) of them a YIDD
mutation. The other 4 (36%) patients presented the wild type virus, and
in the 12th patient, sequencing was not possible as no DNA amplification
of this region was obtained after several PCR attempts.
At the time samples were collected for sequencing the YMDD motif,
8 out of the 11 patients were under lamivudine treatment (period of 6 to
24 months, average 12.5 months). In the other 3 patients, treatment had
been withdrawn at 2 (one patient) and 8 months (2 patients) before the
mutation analysis, and all showed the wild type YMDD motif
All 7 patients with resistance mutation were HBeAg positive at
baseline. A detailed analysis of YMDD mutations during and after
withdrawal of lamivudine will be described elsewhere.
DISCUSSION
The recent introduction of the drug lamivudine added a new
expectative to the treatment of Chronic Hepatitis B (CHB). In the present
study, in agreement with previous results using Abbott Genostics liquid
hybridization assay6, 26, a gradual or a rapid decrease in HBV-DNA levels
was observed. This pattern was detected by the three different quantitative
methods: end-point dilution (EPD), Amplicor Monitor and branched
DNA (bDNA). The EPD method with 10-fold serial dilutions was also
used by YOTSUYANAGI et al. who described a highly sensitive detection
limit (10 copies per reaction) 36.
Other studies reported higher rates of HBV-DNA suppression after
lamivudine therapy at week 24 or 527,11,20. However, their quantification
methodology was based on the solution hybridization assay (Abbott),
with a detection limit of 1.6 to 2.0 pg/ml, corresponding to 4.5x105 to
5.6x105 genomes/ml4,6,20,31. Concentrations calculated by the Abbott assay
were approximately 40 to 100 fold and 35 fold lower than those obtained
when the same sample was tested by the Quantiplex and Hybrid Capture
System HBV-DNA assays, respectively4,17,31. On the other hand, like us,
LAU et al. observed a lower rate of response when using a quantitative
PCR method21.
The HBV-DNA levels were found to be low or undetectable at the
sixth month of therapy in our patients. However, in patients with low
HBV-DNA levels at base line, only the quantitative PCR-based
methodology was able to show variation in viremia. Therefore, some
patients with low levels at baseline would not have been treated if
selection had been based only on bDNA determinations. As emphasized
by HADZIYANNIS10, quantification of HBV-DNA in sera by techniques
with a detection limit of at least 1,000 copies/ml is recommendable for
both the inclusion of low-viremia patients in treatment trials as well as
for evaluating therapy efficacy.
Supporting data for the hypothesis that persistent low degree of
viremia (detected only by PCR quantitative methods) is clinically relevant
were shown by the evolution of our non-responder patients at the sixth
month. All but one of the 12 non-responder patients persisted with
positive PCR and a viral load from 103 to 107 genomes/ml and out of
these 11, seven patients showed a progressive increase of viremia and a
resistance mutation in the YMDD motif. Conversely, all but one of the
23 responder patients (PCR negative at the sixth month) persisted as
such after 12 months of therapy. These results suggest that highly sensitive
PCR assays will be useful for evaluating new drugs and therapy
regimens31 and that a negative PCR at the sixth month is an useful criterion
for determining response to lamivudine.
Our results also showed that non-response to lamivudine is mainly
observed in serum of patients with high viremia and, most of them,
positive for HBeAg. This correlation was so significant that a proportion
between probability of non-response and increase in the logarithm of
genome copies per ml could be established (Figure 1). MUTIMER et
al.24 showed that high titers of hepatitis B virus in serum of pre-treated
patients predicted failure of lamivudine prophylaxis and graft re-infection
after liver transplantation.
Mutations in the YMDD motif were observed only in non-responder
patients with high viremia and positive HBeAg. If we take into
consideration only the first 12 months of treatment, 33% of our patients
(5/15) presented such mutation - which is comparable to the frequency
obtained by HONKOOP et al. (39%, in 14 patients)13, but higher than
the one reported by LAI et al. (14%, in 335 patients)20 - both within the
same therapy period. Furthermore, if we consider the full length of our
treatment (24 months), the frequency of mutation carriers was even
higher: 47% (7 out of 15 patients).
In a later paper, HONKOOP et al. calculated an actuarial cumulative
incidence of YMDD mutation carriers of 32% and 53% after 52 and 78
weeks, respectively, of lamivudine therapy in 15 patients treated for more
than 12 months14.
According to LAU et al., lamivudine resistance tends to appear
specially in patients whose serum levels of HBV-DNA persist above
1,000 Eq/ml21.
The response frequency found in HBeAg-negative patients was 85%;
higher than that reported by TASSOUPOULOS et al. patients with the
same serological profile (63%), probably because we included patients
with low viremia, not detected by the bDNA method employed by these
workers33. Interestingly, 27% of patients in the Tassoupoulos’ study
showed YMDD variant at week 52. This mutation was not observed by
us in HBeAg negative patients.
It is worth mentioning that one patient became HBeAg negative,
despite the detection of a YVDD mutation to lamivudine resistance. This
fact was also observed by GARRETT et al.9.
Another important point is that the response to lamivudine did not
depend on the presence or absence of liver cirrhosis. Furthermore, the
tolerance to lamivudine was equally good in both situations, even in
patients with ascitis (Child Pugh B).
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Summing up, two important conclusions arose from our observations:
first, patients positive for HBeAg and with a high viral load are less
prone to respond to lamivudine as monotherapy due to the high risk of
drug resistance and selection of mutation in the YMDD motif; second,
patients negative for HBeAg generally showed good response to
lamivudine, even in case of liver cirrhosis or of high viremia. A longer
follow-up for these and other patients with YMDD mutation will be
described elsewhere.
RESUMO
Fatores preditivos para resposta da lamivudine
na hepatite crônica B
Introdução: A Lamivudina tem-se mostrado útil no tratamento da
hepatite crônica pelo vírus B (HC-VHB).
Objetivo: Investigar os fatores preditivos da resposta à Lamivudina
na HC-VHB.
Material e Métodos: Estudo prospectivo com Lamivudina em 35
pacientes com HC-VHB e evidência de multiplicação viral,
independentemente do resultado do AgHBe. Administrou-se a
Lamivudina na dose diária de 300 mg por 12 meses, seguida de 150 mg
diários. Critério de resposta: DNA-VHB negativo (por técnica de PCR)
aos 6 meses de tratamento. Nos pacientes não respondedores,
pesquisaram-se mutações associadas com resistência à Lamivudina,
através do sequenciamento do DNA viral.
Resultados: Observou-se resposta em 23/35 pacientes (65,7%). Dos
15 pacientes com AgHBe positivo antes do tratamento, apenas 5 (33,3%)
responderam. As variáveis prévias ao tratamento que puderam prever
uma má resposta foram: AgHBe positivo (p = 0,006), carga viral elevada
(> 3 x 106 genomas/ml) (p = 0,004) e AgHBc no tecido positivo (p =
0,0028). Mutações na região YMDD foram detectadas em 7/11 pacientes
não respondedores.
Conclusões: Pacientes com AgHBe positivo e com alta carga viral
apresentam um alto risco de desenvolver resistência à Lamivudina. Por
outro lado, pacientes com AgHBe negativo, mesmo com alta carga viral,
mostraram uma boa resposta à Lamivudina.
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